Oritavancin diphosphate

CAS No.	192564-14-0	Cat. No.	BCP24660
Name	Oritavancin diphosphate
Synonyms	LY333328 diphosphate; LY-333328 diphosphate; LY 333328 diphosphate;
Formula	C86H103Cl3N10O34P2	M. Wt	1989.1

Description	Oritavancin diphosphate is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections.Oritavancin, also known as LY333328, is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin was more active than either metronidazole or vancomycin against strains of Clostridium difficile tested. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. The 4'-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria. It also acts by inhibition of transglycosylation and inhibition of transpeptidation.
Pathways	Microbiology/Virology
Targets	Antibiotic

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.